drugset / Trial / NCT01555970
Efficacy Study of add-on Therapy With N-Acetylcysteine in Resistant Obsessive-compulsive Disorder
Phase 2
Completed
40 enrolled
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to determine if N-Acetylcysteine (NAC) has efficacy as an augmentation agent in the treatment of treatment-resistant obsessive-compulsive disorder (OCD). The investigators predict that NAC will reduce OCD symptoms after sixteen weeks of add-on treatment as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).
Timeline
- Start
- 2012-03
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 3000 mg | — |